Great exemplar for the ideal mAb co-formulation use case: (i) orthogonal, clearly additive biological axes; (ii) much harder for a bsAb to consistently saturate individual pharmacology of one soluble & one membrane-bound target simultaneously $ABBV $SYRE
a4b7 biosim (vedolizumab) is already out, Sandoz is developing a Skyrizi Il23 biosim (LOE 2033), so that's 2/3 of its combo strategy... where is the IP moat?
SPY120: Co-formulation combination of SPY001 (anti-α4β7) + SPY002 (anti-TL1A) in Phase 2 SKYLINE trial for UC.
SPY130: Co-formulation combination of SPY001 (anti-α4β7) + SPY003 (anti-IL-23) in Phase 2 SKYLINE trial for UC.
SPY230: Co-formulation combination of SPY002 (anti-TL1A) + SPY003 (anti-IL-23) in Phase 2 SKYLINE trial for UC and immune-mediated diseases.
This! Co-formulation is the way (don't believe us - see $ABBV CEO note, see $JNJ see $SYRE. CoFormBio is first AI/SI immunology company focused on solving the efficacy cliff with rapid development combination therapies of validated targets with novel co-formulation IP, powered by our AI/SI engine, CoFormForge. It is not an afterthought/pivot or pipeline rescue strategy for us. It is our strategy. If you are a believer - drop a dm.
@RecursiveChris@mkoeris@Tesla 🎯 again I don’t love the tech/auto analogue BUT their respective “halo” or moonshot tech products showcasing the bleeding edge of innovation, often trickles down to, and benefits consumer accessible products…